文献速递妇科

卵巢癌诊疗的风险调整模型及高性能医院可及性差异

A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
PubMed 文献 · Obstet Gynecol · 2020-01-01

基于加州癌症登记库1996-2014年30,051例I-IV期浸润性上皮性卵巢癌患者的回顾性人群研究,验证观察/预期比值作为风险调整的医院质量指标,并识别高性能医院可及性差异。高观察/预期比值医院提供指南依从性诊疗的比例更高(53.3% vs 37.8% vs 27.5%,P<.001),中位疾病特异性生存更长(73.0 vs 48.1个月,P<.001)。西班牙裔、Medicare保险、合并症评分≥2及低社会经济地位是高性能医院可及性的独立负向预测因素。

要点

  • 高观察/预期比值医院指南依从性更高(53.3%),生存更优(中位73.0个月)。
  • 西班牙裔、Medicare保险、合并症评分≥2及低社会经济地位者高性能医院可及性更低。
  • 基于观察/预期比值的医院分类可用于疑似卵巢癌患者的分诊。

核心结论

  • 在高观察/预期比值医院接受卵巢癌诊疗是生存改善的独立预测因素。
  • 高性能医院可及性障碍因社会人口学特征对患者产生不成比例的影响。

研究设计与样本

  • 回顾性人群研究,纳入1996-2014年加州癌症登记库报告的30,051例I-IV期浸润性上皮性卵巢癌患者,分布于426家医院。
  • 采用风险调整的logistic回归模型计算每家医院的观察/预期比值,按医院年病例量分层。
  • 使用Cox比例风险模型进行生存分析,多变量logistic回归模型识别高性能医院可及性的独立预测因素。

主要发现

  • 低观察/预期比值医院(n=304)覆盖23.5%病例,中比值(n=92)覆盖57.8%,高比值(n=30)覆盖18.7%。
  • 高观察/预期比值医院提供指南依从性诊疗的比例为53.3%,显著高于中比值(37.8%)和低比值(27.5%)医院(P<.001)。
  • 中位疾病特异性生存时间从高观察/预期比值医院的73.0个月至低比值医院的48.1个月(P<.001)。
  • 与高观察/预期比值医院相比,中比值医院死亡风险比HR 1.06(95%CI 1.01-1.11,P<.05),低比值医院HR 1.10(95%CI 1.04-1.16,P<.001)。
  • 西班牙裔(OR 0.85,95%CI 0.78-0.93,P<.001,对比白人)、Medicare保险(OR 0.74,95%CI 0.68-0.81,P<.001,对比管理式医疗)、Charlson合并症指数≥2(OR 0.91,95%CI 0.83-0.99,P<.05)及低社会经济地位(最低五分位OR 0.41,95%CI 0.36-0.46,P<.001,对比最高五分位)为高性能医院可及性的独立负向预测因素。

临床怎么用

  • 可依据基于绩效的观察/预期比值医院分类,对疑似卵巢癌患者进行分诊,以扩大获得专家诊疗的机会。
  • 关注西班牙裔、Medicare保险、合并症负担重及低社会经济地位患者,减少高性能医院可及性障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate the observed/expected ratio for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care, and to identify patient characteristics associated with disparities in access to high-performing hospitals. METHODS: This was a retrospective population-based study of stage I-IV invasive epithelial ovarian cancer reported to the California Cancer Registry between 1996 and 2014. A fit logistic regression model, which was risk-adjusted for patient and disease characteristics, was used to calculate the observed/expected ratio for each hospital, stratified by hospital annual case volume. A Cox proportional hazards model was used for survival analyses, and a multivariable logistic regression model was used to identify independent predictors of access to high-performing hospitals. RESULTS: The study population included 30,051 patients who were treated at 426 hospitals: low observed/expected ratio (n=304) 23.5% of cases; intermediate observed/expected ratio (n=92) 57.8% of cases; and high observed/expected ratio (n=30) 18.7% of cases. Hospitals with high observed/expected ratios were significantly more likely to deliver guideline-adherent care (53.3%), compared with hospitals with intermediate (37.8%) and low (27.5%) observed/expected ratios (P<.001). Median disease-specific survival time ranged from 73.0 months for hospitals with high observed/expected ratios to 48.1 months for hospitals with low observed/expected ratios (P<.001). Treatment at a hospital with a high observed/expected ratio was an independent predictor of superior survival compared with hospitals with intermediate (hazard ratio [HR] 1.06, 95% CI 1.01-1.11, P<.05) and low (HR 1.10, 95% CI 1.04-1.16, P<.001) observed/expected ratios. Being of Hispanic ethnicity (odds ratio [OR] 0.85, 95% CI 0.78-0.93, P<.001, compared with white), having Medicare insurance (OR 0.74, 95% CI 0.68-0.81 P<.001, compared with managed care), having a Charlson Comorbidity Index score of 2 or greater (OR 0.91, 95% CI 0.83-0.99, P<.05), and being of lower socioeconomic status (lowest quintile OR 0.41, 95% CI 0.36-0.46, P<.001, compared with highest quintile) were independent negative predictors of access to a hospital with a high observed/expected ratio. CONCLUSION: Ovarian cancer care at a hospital with a high observed/expected ratio is an independent predictor of improved survival. Barriers to high-performing hospitals disproportionately affect patients according to sociodemographic characteristics. Triage of patients with suspected ovarian cancer according to a performance-based observed/expected ratio hospital classification is a potential mechanism for expanded access to expert care.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bristow RE, Chang J, Villanueva C, et al. A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals. Obstet Gynecol. 2020. PMID: 31923082. doi:10.1097/AOG.0000000000003665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。